Leukemia Clinical Trial
Official title:
Comparative Study of Radiated and Unradiated Leukocyte Transfusions for Patients With Life-threatening Infections: A Collaborative Study by the Leukemia Department and Laboratory Medicine
The goal of this clinical research study is to compare the effectiveness of a white blood cell transfusion with radiated cells to a white blood cell transfusion with cells that have not been radiated. The safety of this procedure will also be studied.
Radiated White Blood Cell Transfusions:
White blood cell transfusions from a volunteer donor may contain blood cells that your body
can react with to produce a disorder called transfusion-associated graft versus host
disease. This means that some of the injected white blood cells can reproduce in your body
and react with your own tissues and create side effects. To avoid this, the blood is
radiated (changed through radiation) to kill all the cells that can divide. But this
radiation also may destroy some of the infection-fighting capacity of the white blood cell
transfusion, this may decrease the effectiveness of these white blood cell transfusions.
Radiating white blood cells is the standard procedure that has been used to treat serious,
life-threatening infections.
Non-Radiated White Blood Cell Transfusions:
If the white blood cells are not radiated, it may increase the effectiveness of these white
cell transfusions. This may help the white blood cells to make more infection-fighting white
blood cells. But, the cells that are also responsible for the transfusion-associated graft
versus host disease will not be killed. This increases the risk that you could have this
complication.
Study Groups:
If you agree to take part in this study, and if you are one of the first 40 patients, you
will be randomly assigned (as in the flip of a coin) to 1 of 2 groups. You or your physician
will not know the results of this randomization. If you are in Group 1, you will have a
non-radiated white blood cell transfusion. If you are in Group 2, you will have a standard
white blood cell transfusion (with radiation). If you are less than 50 years old, you will
receive 4 transfusions of radiated white cells. If you continue to show signs and symptoms
of infection you will receive additional white cell transfusions based on the group you were
randomized to.
If you are after the first 40 patients, you will be placed in a group that the study doctor
thinks will most benefit you. It is important to note that this study is designed as a
"adaptive randomization" which means that as the outcome for each individual is observed,
the next patient receives the product which is most likely to be beneficial and least likely
to be harmful.
White Blood Cell Transfusion:
Before the transfusion, a nurse will take your temperature, breathing rate and blood
pressure. During the transfusion a nurse will watch you closely. Side effects sometimes
occur during and soon after the transfusion. You may be given a drug to help or reduce any
side effects.
If you are in Group 2, you will receive 4 standard white blood cell transfusions (with
radiation).
If you still have an infection after 4 transfusions and the doctor thinks it is necessary,
you will have additional transfusions. You will continue to have transfusions until the
doctor feels the infection has been controlled. If you experience graft-versus-host disease
(GVHD), this will be up to your doctor's discretion.
If you need a white blood cell transfusion for a new infection or for an infection that
comes back, you will receive the same type of transfusion as you received before.
If you were discharged from the hospital and your doctor would like for you to continue
receiving white blood cell transfusions, you will be able to receive them as an outpatient.
Each transfusion will take from 1 hour to several hours depending on how you tolerate the
treatment. Each transfusion will be given daily or as close to daily as possible.
Before every infusion, blood (about 1 tablespoon) will be drawn to measure the number of
white blood cells in your blood.
Length of Study:
You will receive transfusions until your doctor feels the infection has been controlled.
This is an investigational study. White blood cell transfusions are considered standard
procedure for the treatment of serious, life threatening infections.
Up to 150 patients will take part in this study. All will be enrolled at The University of
Texas (UT) MD Anderson Cancer Center.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |